DRL posts consolidated revenues of Rs 37.6 billion, showing seven per cent growth YoY
Gross profit margin were at 61.1 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
DRL announces launch of memantine hydrochloride tablets, USP
It is a therapeutic equivalent generic version of NAMENDA (memantine HCl) tablets in the US market
DRL files Annual Report on Form 20-F
The report was filed with the United States Securities and Exchange Commission recently
DRL in agreement with AstraZeneca Pharma India for Riax and Riax M
DRL will be distributing Riax and Riax M in India
Dr Reddy’s Laboratories (DRL) and AstraZeneca Pharma India have entered into a…
Satish Reddy appointed as Chairman of National Safety Council
He will take over the Chairmanship from Venu Srinivasan, who steered the workings of the Council since July 2011
DRL launches Somazina for stroke patients in India
Partners with global innovator of Citicoline, Ferrer Internacional, Spain, to make Somazina available in India
Satish Reddy appointed as Chairman of National Safety Council
He will take over the Chairmanship from Venu Srinivasan, who steered the workings of the Council since July 2011
DRL, Promius Pharma files NDAs with US FDA
Dr Reddy’s Laboratories and its subsidiary, Promius Pharma announced the filing of three 505(b)(2) New Drug Applications (NDAs)…
DRL and its subsidiary Promius Pharma files three NDAs with US FDA
The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr Reddy’s Proprietary Products group
DRL to acquire select portfolio of UCB’s products business in India
The revenues of the acquired business is approximately Rs 150 crores for calendar year 2014